Showing results (1321-1330 of 1,523) with videos related to
Sort By:
Pageof 153
The New England Journal of Medicine|August 21, 2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S Mok, Yi-Long Wu, Sumitra Thongprasert, et al.Journal of Cancer Research and Clinical Oncology|May 5, 2007
KDR expression is associated with the stage and cigarette smoking of the patients with lung cancerShe-Juan An, Qiang Nie, Zhi-Hong Chen, et al.Eclinicalmedicine|June 8, 2026
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in ChinaChao Zhang, Ben-Yuan Jiang, Li-Xu Yan, et al.Cancer Medicine|May 2, 2026
Age-Associated Targetable Genomic Alterations and PD-L1 Expression in 2509 Patients With Pulmonary Ground-Glass OpacitiesWen-Fang Tang, Si-Qi Huang, Yi-Duo Lin, et al.JTO Clinical and Research Reports|September 16, 2024
Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung AdenocarcinomaJia-Xin Lin, Kai Yin, Li-Xu Yan, et al.Future Oncology (London, England)|October 3, 2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancerBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.The New England Journal of Medicine|April 28, 2025
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Gerrina Ruiter, Myung-Ju Ahn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN StudyBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.The Lancet. Respiratory Medicine|July 19, 2018
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trialZhijie Wang, Ying Cheng, Tongtong An, et al.Translational Lung Cancer Research|September 29, 2021
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment optionsJiu-Wei Cui, Qing Zhou, Shun Lu, et al.Pageof 153